Top Companies in Veterinary Ophthalmic Drugs Market & Their Offerings
Your complete Veterinary Ophthalmic Drugs Market control center is just one click away - Download for Free.
| Companies | Headquarters | Offerings |
| Merck & Co., Inc. | New Jersey, U.S. | Offers veterinary eye care solutions, including infection-control drugs, anti-inflammatory formulations, and prescription therapies for ocular disorders in pets and farm animals. |
| Zoetis | New Jersey, U.S. | Provides a broad portfolio of animal eye health products such as ophthalmic drops, lubricants, anti-infectives, and supportive therapies for companion animals. |
| Dechra Pharmaceuticals | Cheshire, U.K. | Focuses on specialty veterinary medicines, including dry eye therapies, prescription eye solutions, and long-term ocular disease management products. |
| Virbac | Carros, France | Develops eye drops, ointments, gels, and anti-infective formulations designed for routine and chronic eye conditions in animals. |
| Ceva Santé Animale | Libourne, France | Offers veterinary pharmaceutical products for managing eye infections, inflammation, and chronic ophthalmic conditions in companion and livestock animals. |
| Elanco | Indiana, U.S. | Provides advanced animal health therapies, including anti-inflammatory and infection-targeted ophthalmic solutions for pets and farm animals. |
| Bausch & Lomb | Ontario, Canada | Known for ocular lubricants, artificial tears, eye drops, and vision-support products that are also used in veterinary eye care applications. |
What are the Recent Developments in the Veterinary Ophthalmic Drugs Market?
- In January 2026, Dômes Pharma collaborated with the International Society of Veterinary Ophthalmology (ISVO) to launch the Dômes PharmaISVO Travel Scholarship, providing three travel grants to support the training of emerging veterinary ophthalmologists at leading centers.
- In January 2026, Hagyard Equine Medical Institute announced plans to expand its equine ophthalmology services beyond central Kentucky. The move aims to address the shortage of board-certified equine eye specialists, reduce wait times, and provide wider access to advanced diagnostics and surgical care for horses.
Market Growth
The global veterinary ophthalmic drugs market size was estimated at USD 2.14 billion in 2025 and is predicted to increase from USD 2.29 billion in 2026 to approximately USD 4.27 billion by 2035, expanding at a CAGR of 7.14% from 2026 to 2035. The market is growing consistently, supported by increased awareness of animal eye health, higher pet care expenditure, and rising adoption of specialized treatment products.
Supply Chain Analysis
Clinical Trials
- Clinical trials in the veterinary ophthalmic drugs market are increasingly focused on conditions such as glaucoma, cataracts, dry eye (KCS), and corneal infections, with client-owned dogs commonly used in studies. Ongoing research is exploring advanced therapies, including topical dorzolamide for post-surgical ocular hypertension, sustained-release intracanalicular implants for dry eye management, and emerging gene-based treatments for glaucoma.
- Key players: Zoetis, Merck & Co., Dechra Pharmaceuticals, Virbac, and Bausch & Lomb
Regulatory Approvals
- Veterinary ophthalmic drugs must receive approval from regulatory authorities such as the FDA’s Center for Veterinary Medicine (CVM) in the U.S. and the EMA in Europe before commercial launch. The approval process emphasizes product safety, efficacy, and stringent quality parameters, including sterility, stability, and packaging integrity for formulations like eye drops, gels, and ointments.
- Key players: Zoetis, Merck & Co., Elanco, Virbac, and Dechra Pharmaceuticals.
Patient Support and Services
- Patient support in veterinary ophthalmic care aims to enhance treatment effectiveness and adherence by providing clear instructions on proper drug administration, such as timing drops and ointments correctly. Support services include guidance from veterinary pharmacists, educational resources for pet owners, and advanced delivery systems like sustained-release implants or ocular devices for chronic conditions such as glaucoma and dry eye.
- Key players: Bausch & Lomb, Ceva Santé Animale, Elanco, Virbac, and Dechra Pharmaceuticals.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking